H.C. Wainwright analyst Arthur He lowered the firm’s price target on BioAtla to $7 from $10 and keeps a Buy rating on the shares post the Q4 report. The analyst says evalstotug clinical updates are potentially the key drivers in 2024. The firm sees a “catalyst rich” year for BioAtla.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
- BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
- Is BCAB a Buy, Before Earnings?
- BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- BioAtla Rewards Executives for Meeting Performance Goals
